Alkermes (ALKS)
NASDAQ: ALKS
· Real-Time Price · USD
29.82
-0.96 (-3.12%)
At close: Jun 13, 2025, 3:59 PM
29.83
0.03%
After-hours: Jun 13, 2025, 04:20 PM EDT
-3.12% (1D)
| Bid | 29.5 |
| Market Cap | 4.92B |
| Revenue (ttm) | 1.51B |
| Net Income (ttm) | 352.71M |
| EPS (ttm) | 2.1 |
| PE Ratio (ttm) | 14.2 |
| Forward PE | 17.49 |
| Analyst | Buy |
| Ask | 32 |
| Volume | 1,949,910 |
| Avg. Volume (20D) | 1,694,073 |
| Open | 30.50 |
| Previous Close | 30.78 |
| Day's Range | 29.57 - 30.62 |
| 52-Week Range | 22.90 - 36.45 |
| Beta | 0.42 |
About ALKS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALKS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALKS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+6.29%
Alkermes shares are trading higher after the compa...
Unlock content with
Pro Subscription
10 months ago
+6.04%
Alkermes shares are trading higher after the company reported better-than-expected Q2 financial results.
1 month ago · seekingalpha.com
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial PossibleThe company's drug LYBALVI, approved for adults with Schizophrenia and bipolar I disorder, shows potential for label expansion to include pediatric patients to potentially boost revenue growth. The on...
